Since ISB2001 is an exceedingly potent trispecific TCE, it may nonetheless present a differentiated and more efficacious clinical profile in light of its more profound anti-tumor activity in pre-clinical models and its relative imperviousness to combined soluble BCMA, CD38 and APRIL that are often co-circulating at high levels in MM patients (75). The gene discussed is CD38; the disease is neoplasm.